Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Azathioprine, a purine antimetabolite immunosuppressant, photosensitizes the skin and causes the production of mutagenic reactive oxygen species. It is postulated to increase the risk of squamous cell carcinoma (SCC) and other skin cancers in organ transplant recipients (OTRs), but evidence from multiple, largely single-center studies to date has been inconsistent. We aimed to resolve the issue of azathioprine's carcinogenicity by conducting a systematic review of the relevant literature and pooling published risk estimates to evaluate the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KCs) overall and other skin cancers in relation to azathioprine treatment. Twenty-seven studies were included in total, with risk estimates from 13 of these studies able to be pooled for quantitative analysis. The overall summary estimate showed a significantly increased risk of SCC in relation to azathioprine exposure (1.56, 95% confidence interval [CI] 1.11-2.18). No significant associations between azathioprine treatment and BCC (0.96, 95% CI 0.66-1.40) or KC (0.84, 95% CI 0.59-1.21) risk were observed. There was significant heterogeneity between studies for azathioprine risk estimates and the outcomes of SCC, BCC and KC. The pooled findings of available evidence support the contention that treatment with azathioprine increases the risk of SCC in OTRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“This value ranges from 0% to 100%, with values of 25%, 50% and 75% representing low, moderate and high heterogeneity, respectively (33).”
BackgroundBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Statistical analysis A random effects meta-analysis model was used to calculate the pooled estimate and account for the heterogeneity between studies (30).”
Methodvon Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
(2014) · Medical Entomology and Zoology · Cited by 17,633
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955 · cited 1×
“Publication bias was assessed by visual inspection of funnel plots and the Begg and Egger tests (34,35).”
MethodThe combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380 · cited 1×
“Cochran’s Q test was applied to test for statistical heterogeneity among the pooled estimates (31).”
MethodGrulich, A. E., van Leeuwen, M. T., Falster, M. O., & Vajdic, C. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61050-2 · Cited by 2,323
A systematic review of worldwide incidence of nonmelanoma skin cancer
Lomas, A., Leonardi‐Bee, J., & Bath‐Hextall, F. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10830.x · Cited by 1,937 · cited 1×
“Several studies based the outcome assessment on registry data, which has significant limitations with regard to skin cancer reporting (1,63).”
BackgroundSkin cancers after organ transplantation
Euvrard, S., Kanitakis, J., & Claudy, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022137 · Cited by 1,575
Jensen, P., Hansen, S., Møller, B., Leivestad, T., Pfeffer, P., Geiran, O., Fauchald, P., & Simonsen, S. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70185-4 · Cited by 871
Long-term survival in renal transplant recipients with graft function
Ojo, A. O., Hanson, J. A., Wolfe, R. A., Leichtman, A. B., Agodoa, L. Y., & Port, F. K. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00816.x · Cited by 810
Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745 · cited 1×
“However, doses of immunosuppressant medication vary widely between graft organs, and some studies have suggested that it is dosage, rather than individual drugs, that is a significant risk factor for skin cancer (3,58,61,62).”
BackgroundINCIDENCE OF SKIN CANCER AFTER RENAL TRANSPLANTATION IN THE NETHERLANDS
HARTEVELT, M. M., BAVINCK, J. N. B., KOOTTE, A. M. M., VERMEER, B. J., & VANDENBROUCKE, J. P. (1990) · Transplantation · doi:10.1097/00007890-199003000-00006 · Cited by 694
Azathioprine and UVA Light Generate Mutagenic Oxidative DNA Damage
O'Donovan, P., Perrett, C. M., Zhang, X., Montaner, B., Xu, Y.-Z., Harwood, C. A., McGregor, J. M., Walker, S. L., Hanaoka, F., & Karran, P. (2005) · Science · doi:10.1126/science.1114233 · Cited by 631 · cited 5×
“Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HR, hazard ratio; KC, keratinocyte cancer; KS, Kaposi’s sarcoma; MCC, Merkel cell carcinoma; MPA, mycophenolic acid; OR, odds ratio; OTR, organ transplant recipient; RR, relative risk; SCC, squamous cell carcinoma; SC, skin cancer; UVA, ultraviolet A R…”
BackgroundInfluentialSirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., Broeders, N., del Marmol, V., Chatelet, V., Dompmartin, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204166 · Cited by 593 · cited 1×
“Comparisons between azathioprine and cyclosporine, MPA or tacrolimus were recorded, but mechanistic target of rapamycin (mTOR) inhibitors and corticosteroids were excluded, as corticosteroid use is generally universal and mTOR inhibitors may inhibit skin cancer formation (23,24).”
BackgroundLong-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center
Jain, A., Reyes, J., Kashyap, R., Dodson, S. F., Demetris, A. J., Ruppert, K., Abu-Elmagd, K., Marsh, W., Madariaga, J., Mazariegos, G., et al. (2000) · Annals of Surgery · doi:10.1097/00000658-200010000-00004 · Cited by 559
THE RISK OF SKIN CANCER IN RENAL TRANSPLANT RECIPIENTS IN QUEENSLAND, AUSTRALIA: A Follow-up Study1
Bavinck, J. N. B., Hardie, D. R., Green, A., Cutmore, S., MacNaught, A., O'Sullivan, B., Siskind, V., van der Woude, F. J., & Hardie, I. R. (1996) · Transplantation · doi:10.1097/00007890-199603150-00008 · Cited by 493 · cited 5×
“Three studies included SCC in situ (39,44,51), and the remaining five evaluated BCC and SCC alone (2,21,37,38,43).”
BackgroundInfluentialSelf-citationNon-melanoma skin cancer risk in the Queensland renal transplant population
Ramsay, H. M., Fryer, A. A., Hawley, C. M., Smith, A. G., Nicol, D. L., & Harden, P. N. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04976.x · Cited by 277
Wong, W. C., Cheung, C. S., & Hart, G. J. (2008) · Emerging Themes in Epidemiology · doi:10.1186/1742-7622-5-23 · Cited by 257 · cited 1×
“The quality of studies was assessed using a scoring system based on the following guidelines: Meta-analysis of Observational Studies in Epidemiology (MOOSE) (26), Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (27), Quality Assessment Tool for Systematic Reviews of Observational Studies…”
MethodCampbell, S. B., Walker, R., Tai, S. S., Jiang, Q., & Russ, G. R. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04004.x · Cited by 221 · cited 1×
“Comparisons between azathioprine and cyclosporine, MPA or tacrolimus were recorded, but mechanistic target of rapamycin (mTOR) inhibitors and corticosteroids were excluded, as corticosteroid use is generally universal and mTOR inhibitors may inhibit skin cancer formation (23,24).”
BackgroundRisk of Merkel Cell Carcinoma After Solid Organ Transplantation
Clarke, C. A., Robbins, H. A., Tatalovich, Z., Lynch, C. F., Pawlish, K. S., Finch, J. L., Hernandez, B. Y., Fraumeni, J. F., Madeleine, M. M., & Engels, E. A. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju382 · Cited by 217 · cited 10×
“Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HR, hazard ratio; KC, keratinocyte cancer; KS, Kaposi’s sarcoma; MCC, Merkel cell carcinoma; MPA, mycophenolic acid; OR, odds ratio; OTR, organ transplant recipient; RR, relative risk; SCC, squamous cell carcinoma; SC, skin cancer; UVA, ultraviolet A R…”
BackgroundResultInfluentialSu, F., Yu, L., Berry, K., Liou, I. W., Landis, C. S., Rayhill, S. C., Reyes, J. D., & Ioannou, G. N. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.043 · Cited by 205
Guidelines for the Management of Squamous Cell Carcinoma in Organ Transplant Recipients
STASKO, T., BROWN, M. D., CARUCCI, J. A., EUVRARD, S., JOHNSON, T. M., SENGELMANN, R. D., STOCKFLETH, E., & TOPE, W. D. (2004) · Dermatologic Surgery · doi:10.1097/00042728-200404020-00012 · Cited by 181
Wimmer, C.-D., Rentsch, M., Crispin, A., Illner, W.-D., Arbogast, H., Graeb, C., Jauch, K.-W., & Guba, M. (2007) · Kidney International · doi:10.1038/sj.ki.5002154 · Cited by 176
Euvrard, S., Kanitakis, J., Decullier, E., Butnaru, A. C., Lefrançois, N., Boissonnat, P., Sebbag, L., Garnier, J.-L., Pouteil-Noble, C., Cahen, R., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000209921.60305.d9 · Cited by 171 · cited 15×
“The single study excluded from the quantitative analysis found no association between different immunosuppression regimens and SCC risk (risk estimates not reported) (50).”
BackgroundInfluentialAriyaratnam, J., & Subramanian, V. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.451 · Cited by 165 · cited 1×
“A meta-analysis of patients with inflammatory bowel disease found an increased risk of KCs in patients treated with azathioprine when compared with healthy controls or controls with inflammatory bowel disease but no azathioprine exposure (22).”
BackgroundWebb, M. C., Compton, F., Andrews, P. A., & Koffman, C. G. (1997) · Transplantation Proceedings · doi:10.1016/s0041-1345(96)00152-2 · Cited by 163 · cited 1×
“It is also possible that because the incidence of BCC increases linearly following transplantation, whereas SCC rises exponentially, a greater number of studies with a lengthy follow-up period are required to accurately assess the influence of azathioprine on BCC risk (56).”
BackgroundAzathioprine treatment photosensitizes human skin to ultraviolet A radiation
Perrett, C. M., Walker, S. L., O’Donovan, P., Warwick, J., Harwood, C. A., Karran, P., & McGregor, J. M. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08610.x · Cited by 152 · cited 4×
“Azathioprine, a purine antimetabolite immunosuppressant, is thought to additionally heighten SCC risk via photosensitization (14,15) and an accumulation of 6-thioguanine in DNA, which causes the production of mutagenic reactive oxygen species when exposed to ultraviolet A (UVA) (16).”
BackgroundInfluentialMelanoma Risk and Survival among Organ Transplant Recipients
Robbins, H. A., Clarke, C. A., Arron, S. T., Tatalovich, Z., Kahn, A. R., Hernandez, B. Y., Paddock, L. E., Yanik, E. L., Lynch, C. F., Kasiske, B. L., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.312 · Cited by 152 · cited 4×
“All but three studies combined multiple types of skin cancers (5,6,42), and seven studies combined KCs with other skin cancers (20,45,46,49,52,53,55).”
InfluentialULRICH, C., SCHMOOK, T., SACHSE, M. M., STERRY, W., & STOCKFLETH, E. (2004) · Dermatologic Surgery · doi:10.1097/00042728-200404020-00009 · Cited by 151
Caforio, A. L. P., Fortina, A. B., Piaserico, S., Alaibac, M., Tona, F., Feltrin, G., Pompei, E., Testolin, L., Gambino, A., Volta, S. D., et al. (2000) · Circulation · doi:10.1161/01.cir.102.suppl_3.iii-222 · Cited by 149 · cited 2×
“However, doses of immunosuppressant medication vary widely between graft organs, and some studies have suggested that it is dosage, rather than individual drugs, that is a significant risk factor for skin cancer (3,58,61,62).”
BackgroundIncidence of and Risk Factors for Skin Cancer After Heart Transplant
Brewer, J. D., Colegio, O. R., Phillips, P. K., Roenigk, R. K., Jacobs, M. A., van de Beek, D., Dierkhising, R., Kremers, W. K., McGregor, C. G. A., & Otley, C. C. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.276 · Cited by 131 · cited 16×
“This study is novel in systematically summarizing all available data on azathioprine use and skin cancer risk in OTRs and providing a pooled risk estimate separately for SCC and BCC, with detailed assessment of the methodological quality of included studies.”
BackgroundInfluentialRamsay, H. M., Fryer, A. A., Hawley, C. M., Smith, A. G., Nicol, D. L., & Harden, P. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/s0190-9622(03)00902-2 · Cited by 130 · cited 6×
“Risk factors for developing SCC after organ transplant include older age at transplantation, fair skin type, high sun exposure, frequent sunburns in childhood, a history of skin cancer pretransplantation and rejection episodes in the first year of transplantation (47,57,58).”
BackgroundInfluentialFortina, A. B., Piaserico, S., Caforio, A. L. P., Abeni, D., Alaibac, M., Angelini, A., Iliceto, S., & Peserico, A. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.9.1079 · Cited by 129 · cited 1×
“However, doses of immunosuppressant medication vary widely between graft organs, and some studies have suggested that it is dosage, rather than individual drugs, that is a significant risk factor for skin cancer (3,58,61,62).”
BackgroundHIESSE, C., Rieu, P., Kriaa, F., Larue, J. R., Goupy, C., Neyrat, N., & Charpentier, B. (1997) · Transplantation Proceedings · doi:10.1016/s0041-1345(96)00153-4 · Cited by 124 · cited 1×
“Additionally, some studies examined azathioprine use with any combination of immunosuppressants, others outlined specific regimens and several studies did not provide any treatment detail despite the demonstrated importance of treatment combinations (3,59,60).”
BackgroundIncidence and clinical course of de-novo malignancies in renal allograft recipients
Winkelhorst, J. T., Brokelman, W. J. A., Tiggeler, R. G. W. L., & Wobbes, T. (2001) · European Journal of Surgical Oncology · doi:10.1053/ejso.2001.1119 · Cited by 117 · cited 1×
“As the most common malignancy posttransplantation, skin cancer represents a major cause of morbidity and mortality in this population (8,9).”
BackgroundMalignancy After Renal Transplantation: Incidence and Role of Type of Immunosuppression
Tremblay, F. M., Fernandes, M., Habbab, F., de Edwardes, M. D. B., Loertscher, R., & Meterissian, S. H. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02574501 · Cited by 110
Incidence and risk factors for skin cancer following lung transplantation
Rashtak, S., Dierkhising, R., Kremers, W. K., Peters, S. G., Cassivi, S. D., & Otley, C. C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.09.010 · Cited by 97 · cited 19×
“This study is novel in systematically summarizing all available data on azathioprine use and skin cancer risk in OTRs and providing a pooled risk estimate separately for SCC and BCC, with detailed assessment of the methodological quality of included studies.”
BackgroundResultInfluentialGogia, R., Binstock, M., Hirose, R., Boscardin, W. J., Chren, M., & Arron, S. T. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.09.030 · Cited by 92 · cited 1×
“Risk factors for developing SCC after organ transplant include older age at transplantation, fair skin type, high sun exposure, frequent sunburns in childhood, a history of skin cancer pretransplantation and rejection episodes in the first year of transplantation (47,57,58).”
BackgroundTessari, G., Naldi, L., Boschiero, L., Nacchia, F., Fior, F., Forni, A., Rugiu, C., Faggian, G. G., Sassi, F., Gotti, E., et al. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2009.377 · Cited by 88
Immunosuppression and Other Risk Factors for Lip Cancer after Kidney Transplantation
van Leeuwen, M. T., Grulich, A. E., McDonald, S. P., McCredie, M. R. E., Amin, J., Stewart, J. H., Webster, A. C., Chapman, J. R., & Vajdic, C. M. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0919 · Cited by 86 · cited 3×
“All but three studies combined multiple types of skin cancers (5,6,42), and seven studies combined KCs with other skin cancers (20,45,46,49,52,53,55).”
BackgroundResultIncidence and Risk Factors for Nonmelanoma Skin Cancer After Heart Transplantation
Molina, B. D., Leiro, M. G. C., Pulpón, L. A. A., Mirabet, S., Yañez, J. F., Bonet, L. A., Vílchez, F. G., Delgado, J. F., Manito, N., Rábago, G., et al. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.08.003 · Cited by 82 · cited 23×
“This study is novel in systematically summarizing all available data on azathioprine use and skin cancer risk in OTRs and providing a pooled risk estimate separately for SCC and BCC, with detailed assessment of the methodological quality of included studies.”
BackgroundResultInfluentialMudigonda, T. V., Levender, M. M., OʼNeill, J. L., West, C. E., Pearce, D. J., & Feldman, S. R. (2012) · Dermatologic Surgery · doi:10.1111/dsu.12028 · Cited by 79
Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure
Terhorst‐Molawi, D., Drecoll, U., Stockfleth, E., & Ulrich, C. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09454.x · Cited by 65 · cited 4×
“All but three studies combined multiple types of skin cancers (5,6,42), and seven studies combined KCs with other skin cancers (20,45,46,49,52,53,55).”
BackgroundInfluentialMackenzie, K. A., Wells, J. E., Lynn, K. L., Simcock, J., Robinson, B. A., Roake, J., & Currie, M. J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp482 · Cited by 63 · cited 1×
“Three studies included SCC in situ (39,44,51), and the remaining five evaluated BCC and SCC alone (2,21,37,38,43).”
BackgroundZavos, G., Karidis, N. P., Tsourouflis, G. S., Bokos, J., Diles, K., Sotirchos, G., Theodoropoulou, E., & Kostakis, A. I. (2011) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2011.04939.x · Cited by 55
Shuttleworth, D., Marks, R., Griffin, P., & Salaman, J. R. (1989) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1989.tb01330.x · Cited by 51
Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine.
Sheil, A. G. R., Flavel, S., Disney, A. P. S., Mathew, T. H., & Hall, B. M. (1987) · PubMed · Cited by 47
Geusau, A., Dunkler, D., Messeritsch, E., Sandor, N., Heidler, G., Rödler, S., Ankersmit, H. J., Zuckermann, A. O., & Tschachler, E. (2008) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2008.03711.x · Cited by 45 · cited 1×
“Three studies included SCC in situ (39,44,51), and the remaining five evaluated BCC and SCC alone (2,21,37,38,43).”
BackgroundSkin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern
Keller, B., Braathen, L. R., Marti, H., & Hunger, R. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13036 · Cited by 43 · cited 14×
“This study is novel in systematically summarizing all available data on azathioprine use and skin cancer risk in OTRs and providing a pooled risk estimate separately for SCC and BCC, with detailed assessment of the methodological quality of included studies.”
BackgroundInfluentialOtley, C. C. (2000) · Dermatologic Surgery · doi:10.1046/j.1524-4725.2000.00091.x · Cited by 39
Tanner, J., & Menézes, J. (1994) · Blood · doi:10.1182/blood.v84.11.3956.bloodjournal84113956 · Cited by 39
Sanders, M. L., Karnes, J. H., Denny, J. C., Roden, D. M., Ikizler, T. A., & Birdwell, K. A. (2015) · Transplantation Direct · doi:10.1097/txd.0000000000000521 · Cited by 38 · cited 17×
“This study is novel in systematically summarizing all available data on azathioprine use and skin cancer risk in OTRs and providing a pooled risk estimate separately for SCC and BCC, with detailed assessment of the methodological quality of included studies.”
BackgroundInfluentialWisgerhof, H. C., van der Boog, P. J. M., de Fijter, J. W., Wolterbeek, R., Haasnoot, G. W., Claas, F. H. J., Willemze, R., & Bavinck, J. N. B. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.181 · Cited by 37
Picard, M., Dang, N. P., D'Incan, M., Mansard, S., Dechelotte, P., Pereira, B., Mondié, J.-M., & Barthélémy, I. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12939 · Cited by 29
Savoia, P., Stroppiana, E., Cavaliere, G., Osella‐Abate, S., Mezza, E., Segoloni, G., & Bernengo, M. G. (2011) · European Journal of Dermatology · doi:10.1684/ejd.2011.1272 · Cited by 22 · cited 3×
“All but three studies combined multiple types of skin cancers (5,6,42), and seven studies combined KCs with other skin cancers (20,45,46,49,52,53,55).”
BackgroundSkin tumours in the West of Scotland renal transplant population
Mackintosh, L. J., Geddes, C., & Herd, R. M. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12129 · Cited by 20 · cited 3×
“All but three studies combined multiple types of skin cancers (5,6,42), and seven studies combined KCs with other skin cancers (20,45,46,49,52,53,55).”
BackgroundMalignancy in Kidney Transplantation: A 25-Year Single-center Experience in Portugal
Aguiar, B., Amorim, T. S., Romãozinho, C., Santos, L., Macario, F. J. G. R. M., Alves, R., Campos, M., & Mota, A. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.03.039 · Cited by 20 · cited 1×
“As the most common malignancy posttransplantation, skin cancer represents a major cause of morbidity and mortality in this population (8,9).”
BackgroundHayashida, M. Z., Fernandes, V. M. C., Fernandes, D. R. D. M., Ogawa, M. M., & Tomimori, J. (2015) · International Journal of Dermatology · doi:10.1111/ijd.12632 · Cited by 19
Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern
Keller, B., Braathen, L. R., Marti, H.-P., & Hunger, R. E. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.12904 · Cited by 14
Cited by
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology
Broen, J. C. A., & van Laar, J. M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0374-8 · Cited by 235
Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma
Andersen, Y. M. F., Egeberg, A., Skov, L., & Thyssen, J. P. (2017) · Current Dermatology Reports · doi:10.1007/s13671-017-0168-7 · Cited by 62
Metadata
- Authors
- Jiyad, Z., Olsen, C. M., Burke, M. T., Isbel, N. M., & Green, A. C.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 16
- Issue
- 12
- Pages
- 3490-3503
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W2390922210
- Cited by
- 219
- References
- 64
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.